NCT07587723 A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
| NCT ID | NCT07587723 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novartis Pharmaceuticals |
| Condition | Immune Thrombocytopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-06-25 |
| Primary Completion | 2028-09-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2026-06-25 with a primary completion date of 2028-09-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy. This study will use secondary data provided by health care professionals (HCPs) for a sample of primary ITP patients, and primary data from a structured HCP survey. Data will be collected from HCPs working in various clinical centers across the United States (US), United Kingdom (UK), and Germany.
Eligibility Criteria
Inclusion criteria: HCP inclusion criteria: 1. A licensed HCP (e.g., internal medicine specialist, hematologist, hematologist-oncologist or immunologist etc.) involved in the management of adult patients with primary ITP. 2. Actively involved in treatment decision-making for primary ITP patients at the time of the study. 3. Have a minimum of 3 years of experience managing patients with primary ITP. 4. Currently, managing an average of at least 2 adult primary ITP patients per month, including those treated with eltrombopag. 5. Able and willing to complete a web-based survey (approximately 60 to 70 minutes) and abstract data from 2 eligible patient charts. 6. Practicing in one of the study countries (US, UK, or Germany). 7. Have access to a computer or mobile device with internet connectivity to complete the survey. 8. Not listed as inactive or retired in the panel database. Patient-level inclusion criteria: 1. Confirmed diagnosis of primary ITP. 2. Aged ≥18 years at the time of diagnosis. 3. Received first-line corticosteroid therapy (with or without intravenous immune globulin \[IVIg\]). 4. Initiated eltrombopag treatment (with or without corticosteroids) as first non-steroidal ITP treatment between 01 January 2020 and 31 December 2024. 5. Have at least 6 months of follow-up data available after the index date (unless deceased within that period). Exclusion criteria: HCP exclusion criteria: 1. Currently employed by a pharmaceutical company or regulatory authority involved in the approval or marketing of treatments for primary ITP. 2. Unable to provide data for patients who meet the study's inclusion criteria. 3. Not currently managing patients with primary ITP or are not involved in treatment decisions for these patients. Patient-level exclusion criteria: 1\. Diagnosis of Evans syndrome, secondary ITP, or non-immune thrombocytopenia.
Contact & Investigator
Novartis Pharmaceuticals
STUDY DIRECTOR
Novartis Pharmaceuticals
Frequently Asked Questions
Who can join the NCT07587723 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Immune Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07587723 currently recruiting?
Yes, NCT07587723 is actively recruiting participants. Contact the research team at novartis.email@novartis.com for enrollment information.
Where is the NCT07587723 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT07587723 clinical trial?
NCT07587723 is sponsored by Novartis Pharmaceuticals. The principal investigator is Novartis Pharmaceuticals at Novartis Pharmaceuticals. The trial plans to enroll 150 participants.